ClinicalTrials.gg
RecruitingNCT07188779RADA16 for PedUpdated Jul 22, 2026

Impact of RADA16 Use on Outcomes Following Tonsillectomy in Children

A Phase 2 interventional study of RADA16 hydrogel in Postoperative Pain, sponsored by Rutgers, The State University of New Jersey. Recruiting at 2 sites in United States. Open to participants aged 3 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by Rutgers, The State University of New Jersey · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
134
Allocation
Randomized
Ages
3 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Pain, Postoperative by Rutgers, The State University of New Jersey — 7 open to participants now, 7 under way, 2 of them phase 3. Pain, Postoperative · Rutgers, The State University of New Jersey.

Started
2026
with 4 others
Phase 2
3 of 10
2 open now
Registered
7th of 10
by date

Among the 10 studies in Pain, Postoperative by Rutgers, The State University of New Jersey, this one is one of 5 that started in 2026, is one of 3 in phase 2, and was the 7th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

7 of the 10 studies in Pain, Postoperative by Rutgers, The State University of New Jersey are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 3 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Pain, Postoperative by Rutgers, The State University of New Jersey, or all of them as a file.
02

Study summary

The purpose of the research is to determine if RADA16 (also known as PuraStat®, PuraGel®, or PuraSinus®) improves patient outcomes following pediatric tonsillectomy procedures. Researchers will compare application of device RADA16 to application of no device to see if RADA16 works to treat post tonsillectomy hemorrhage.Participants will:

Undergo tonsillectomy procedure. Receive and fill out a survey sent via email every 2 days following their procedure for 15 days, plus an additional survey on day 30, and track their symptoms.

Read the detailed description

This is a prospective study evaluating the impact of intraoperative RADA16 application on the postoperative course following pediatric tonsillectomy as it relates to pain, bleeding, readmission, and use of a rescue analgesic (ex., oxycodone). We propose a randomized controlled trial whereby patients undergoing tonsillectomy would either receive a standard analgesic regimen (postoperative acetaminophen and NSAIDs plus oxycodone as a supplemental analgesic) versus intraoperative RADA16 application plus a standard analgesic regimen.

03

Conditions studied

  • Postoperative Pain

Browse trials for

Keywords

  • tonsillectomy
  • adenoidectomy
  • hemostasis
  • postop complications
04

Who can participate

Ages eligible
3 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Children aged 3-17 years undergoing tonsillectomy +/- adenoidectomy CPT codes

  • 42820 (Tonsillectomy and adenoidectomy; younger than age 12)
  • 42821 (… age 12 or over)
  • 42825 (Tonsillectomy; primary or secondary; younger than age 12)
  • 42826 (… age 12 or over)
  • 42830 (Adenoidectomy, primary; younger than age 12)
  • 42831 (… age 12 or over)
  • 42835 (Adenoidectomy; secondary; younger than age 12)
  • 42836 (… age 12 or over)

Exclusion criteria

Exclusion Criteria:

  • Children with bleeding disorders or other hematologic or taking anticoagulant medications Developmental delay affecting pain reporting Children with known allergies to RADA16 components Children with prior tonsillectomy or tonsillotomy Children undergoing tonsillectomy with concern for cancer, Children taking opioids chronically prior to surgery, Anyone pregnant women, incarcerated individuals, children unable to speak English or Spanish
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
134 participants (estimated)

Study arms

  • Active comparator
    RADA16

    Patients randomized to the treatment arm will undergo application of 2.5% RADA16 hydrogel to the tonsillar fossae following tonsillectomy using a sterile syringe tip applicator. The gel will be spread into a thin layer within the tonsillar fossae. The gel will be left to sit for 60 seconds. A suction device will then be used to remove any excess RADA16 hydrogel, leaving a thin layer of RADA16 over the tonsillar fossae.

    Device: RADA16 hydrogel

  • No intervention
    Control arm

    Patients randomized to the control arm will not undergo application of RADA16 hydrogel following hemostasis with suction monopolar electrocautery.

Interventions

  • DeviceRADA16 hydrogel

    Application of 2.5% RADA16 hydrogel to the tonsillar fossae following tonsillectomy using a sterile syringe tip applicator. The gel will be spread into a thin layer within the tonsillar fossae. The gel will be left to sit for 60 seconds. A suction device will then be used to remove any excess RADA16 hydrogel, leaving a thin layer of RADA16 over the tonsillar fossae.

    Also known as: puragel

06

What researchers measure

Primary outcomes

  1. Postoperative pain

    Pain assessed via the Wong Baker Faces scale. The primary outcome measure will be assessed via online survey on post-operative day one then subsequently every other day until post-operative day fifteen, with a final survey on day 30.

    Time frame: From enrollment to post-operative day 30.

Secondary outcomes

  1. Number of Participants with post-tonsillectomy hemorrhage who receive topical agents

    Number of Participants with post-tonsillectomy hemorrhage who receive topical agents for management of post tonsillectomy hemorrhage

    Time frame: From enrollment to post-operative day 30

  2. Number of Participants with post-tonsillectomy hemorrhage who require a return to the operating room

    Number of Participants with post-tonsillectomy hemorrhage who require a return to the operating room for management of post tonsillectomy hemorrhage

    Time frame: From enrollment to post-operative day 30

  3. Number of participants who require hospital readmission for post tonsillectomy hemorrhage management

    Number of participants who require readmission for management of post tonsillectomy hemorrhage

    Time frame: From enrollment to post-operative day thirty

  4. Number of participants who require a rescue analgesic for management following tonsillectomy procedure

    Number of participants who use a rescue analgesic following their tonsillectomy procedure

    Time frame: From enrollment to post-operative day 30

  5. Days participants take to resume their regular diet post operation

    Recording how many days it takes for participants to return to their regular diet post operation

    Time frame: From enrollment to post-operative day 30

07

Study locations

1 of 2 sites recruiting
  • Cooperman Barnabas Medical Center
    Livingston, New Jersey 07039, United States
    Not yet recruiting
  • University Hospital
    Newark, New Jersey 07103, United States
    Recruiting
08

References and documents

Publications

  • Mitchell RB, Archer SM, Ishman SL, Rosenfeld RM, Coles S, Finestone SA, Friedman NR, Giordano T, Hildrew DM, Kim TW, Lloyd RM, Parikh SR, Shulman ST, Walner DL, Walsh SA, Nnacheta LC. Clinical Practice Guideline: Tonsillectomy in Children (Update). Otolaryngol Head Neck Surg. 2019 Feb;160(1_suppl):S1-S42. doi: 10.1177/0194599818801757. PubMed 30798778 ↗
  • Gerbershagen HJ, Aduckathil S, van Wijck AJ, Peelen LM, Kalkman CJ, Meissner W. Pain intensity on the first day after surgery: a prospective cohort study comparing 179 surgical procedures. Anesthesiology. 2013 Apr;118(4):934-44. doi: 10.1097/ALN.0b013e31828866b3. PubMed 23392233 ↗
  • Pynnonen M, Brinkmeier JV, Thorne MC, Chong LY, Burton MJ. Coblation versus other surgical techniques for tonsillectomy. Cochrane Database Syst Rev. 2017 Aug 22;8(8):CD004619. doi: 10.1002/14651858.CD004619.pub3. PubMed 28828761 ↗

Individual participant data

Plan to share: No — Determining if access to university data can be available for the study

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Dec 2027, 16 months after the start.

Of 90 non-industry phase 2 interventional studies under Pain, Postoperative, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 32. This study's planned 16 months is below that.

Counting every sponsor, half of 139 studies reached it within 12 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2025
First posted
Sep 23, 2025
StartActual
Jul 9, 2026
Primary completionEst.
Dec 1, 2027
CompletionEst.
Dec 1, 2027
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07188779
Responsible party
Wayne Daniel Hsueh, MD (ASSOC PROF-CLIN, Rutgers, The State University of New Jersey) — Principal investigator
First posted
Sep 23, 2025
Start date
Jul 9, 2026
Primary completion
Dec 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Jul 22, 2026

Study contacts

Wayne D Hsueh, MD
Contact
wayne.hsueh@rutgers.edu
973-972-4588
Gabriel Frimpong, MPH, PA
Contact
gf345@njms.rutgers.edu
973-972-2309

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion